Iris claw lens insertion useful in aphakic patients

Article

A recent investigation included in Eye has found that performing Artisan iris claw lens insertion is beneficial in acquired aphakia.

A recent investigation included in Eye has found that performing Artisan iris claw lens insertion is beneficial in acquired aphakia.

The study, led by Dr K.S. Lett, Department of Ophthalmology, University Hospitals of Leicester, Leicester, UK, involved a retrospective analysis of 32 aphakic eyes of 31 patients that had experienced Artisan lens implantation. The follow-up varied between 6 and 42 months, with a mean of 17.3 months. Complicated phacoemulsification was the most common cause of aphakia with 17 of the 32 eyes presenting with it.

Best-corrected visual acuity (BCVA) that exceeded preoperative data was gained in 21 of the 32 eyes included in the evaluation. Preoperative BCVA was matched postoperatively in 10 eyes and one eye presented with a BCVA worse than the preoperative data. This was due to non-arteritic anterior ischaemic, optic neuropathy.

Pre-existing glaucoma or ocular hypertension was found in 4 of the total study eyes. There were no problems with intraocular pressure, uveitis, glaucoma or hyphaema during the follow-up period.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.